South Africa’s pharmaceutical policy must protect patients through affordable medicines. Still, it cannot pursue the lowest possible price at the cost of the local industry that keeps those medicines flowing, an industry expert argues. Writing from years in the sector and doctoral research on generic pricing, the author poses a harder question. What happens when the drive for cheap medicines…
Tag: Pharmisa
-
Single Exit Price to Rise 2.88% as Industry Warns of Shortages
The single exit price for medicines will rise 2.88% from October. The industry warns rising input costs are straining medicine supply. The single exit price (SEP) of medicines and scheduled substances will rise 2.88% from 1 October. This is the second adjustment this year. South Africa’s pharmaceutical industry warns that rising input costs are squeezing medicine supply and triggering shortages.…
-
Local Pharmaceutical Manufacturing Row Deepens
The Department of Health defended its medicine procurement policies after an industry body blamed government tender practices for thousands of job losses. These job losses occurred among South African pharmaceutical manufacturers. The dispute highlights increasing tension between government efforts to support local pharmaceutical manufacturing and the need to secure affordable medicines. However, the Department of Health also needs to secure…
-
Local Pharmaceutical Manufacturing Needs Urgent Support
An industry group has warned that South Africa’s emphasis on securing the lowest possible prices for medicine is excluding local pharmaceutical companies from important state contracts. This issue highlights the challenges faced by local pharmaceutical manufacturing. In particular, they struggle to remain competitive in the market. Pharmaceuticals Made in South Africa (Pharmisa) told Parliament that the Health Department’s procurement policies…
-
Imported Medicines Threaten SA’s Local Pharmaceutical Industry
South Africa’s local pharmaceutical manufacturers have warned that the Department of Health’s growing reliance on imported medicines could place jobs, industrial capacity, and the country’s security of medicine supply at risk. The warning follows analysis by Pharmaceuticals Made in SA (Pharmisa). Their findings show that importers have steadily increased their share of two of the Department of Health’s biggest medicine…
-
SA Pharma Localisation Faces Foreign Investor Pressure
South Africa’s pharmaceutical sector has become a major industrial battleground. The government is pushing hard to localise production and boost public procurement. It also wants to rebuild domestic capacity. However, outside forces are complicating these goals. Trade, Industry and Competition Minister Parks Tau delivered this warning at a recent stakeholder engagement. He noted that foreign investors remain highly interested in…
-
Local Medicine Manufacturing and National Health Security
In a strategic move to enhance local medicine manufacturing, Sahpra aims to fast-track the approval of locally made medicines. This is an effort to secure the national supply. Sahpra’s decision aims to address drug shortages and reduce reliance on imports. Furthermore, it aims to strengthen the nation’s pharmaceutical industry through initiatives in local medicine manufacturing. In a significant move to…
-
African Pharmaceutical Procurement: A Path to Self-Sufficiency
A pooled system for African pharmaceutical procurement is crucial. Africa must reduce its dependence on imported medicines. Delegates at a G20 event reached this conclusion. The discussion highlighted Africa’s vulnerability in its supply chain. The COVID-19 pandemic exposed this. Recent US and European aid cuts emphasised this. The Need for African Pharmaceutical Procurement Africa’s lack of local production is a…